New drug combo tested for aggressive breast cancer
NCT ID NCT02158507
Summary
This small pilot study tested whether combining two drugs—veliparib and lapatinib—could help control metastatic triple negative breast cancer in patients who had already tried other treatments. The main goal was to check if the combination was safe and tolerable, while also looking for early signs that it might slow the cancer. Researchers also collected blood and tumor samples to understand how the drugs worked and who might benefit most.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.